Recent News

ASCO 2021: Post Hoc Subgroup Analyses With Avelumab in Advanced Urothelial Carcinoma

ASCO 2021: 5-Year Update on Pembrolizumab for Advanced Urothelial Cancer

ASCO 2021: KEYNOTE-052 Survival Update on First-Line Pembrolizumab in Advanced Urothelial Cancer

ASCO 2021: Bladder-Sparing Combination Therapy Under Study in Muscle-Invasive Urothelial Cancer

Bladder Cancer Footprint? Fox Chase Researcher Awarded NIH Grant for Diagnostic Urine Test

Multimodal Imaging Strategy Under Study in Urothelial Cell Carcinoma

TROPHY-U-01 Supports Use of Sacituzumab Govitecan-hziy in Metastatic Urothelial Carcinoma

Lymphocyte-to-Monocyte Ratio: Prognostic Marker in Bladder Cancer?

Can Targeting APE1 and SSRP1 Improve Survival in Muscle-Invasive Bladder Cancer?

DNA Methyltransferase Inhibitor Under Study in Cisplatin-Resistant Urothelial Carcinoma

Update on Potential Biomarkers for Predicting Bladder Cancer Lymph Node Metastasis

First-Line Treatments in Metastatic Urothelial Cancer: Real-World Decision-Making

Priority Review Accepted by FDA for Nivolumab in Adjuvant Treatment of Muscle-Invasive Urothelial Cancer

Neoadjuvant Cabazitaxel Plus Cisplatin in Muscle-Invasive Bladder Cancer

Long-Term Outcomes and Costs of BCG Therapy for High-Risk Non–Muscle-Invasive Bladder Cancer

Metastatic Distribution of Urothelial Cancer: Differences Related to Age and Sex

Two sBLAs Accepted by FDA for Enfortumab Vedotin-ejfv in Urothelial Cancer

AACR 2021: Survival Outcomes by Treatment Response From IMvigor130 in Urothelial Cancer

Sacituzumab Govitecan-hziy Granted Accelerated Approval for Advanced Urothelial Carcinoma

Is Adjuvant Atezolizumab Safe and Effective in Muscle-Invasive Urothelial Cancer?

How Metabolic Factors May Influence Bladder Cancer Risk and Mortality

Potential Factors Linked to Patient Discontinuation of Therapy for Bladder Cancer

Adjuvant Durvalumab for Localized Urothelial Cancer

FDA Grants Two New Breakthrough Device Designations for MRD Testing

Radical Cystectomy for Progressive Versus de Novo Muscle-Invasive Bladder Cancer

Perioperative Chemotherapy Versus Surveillance in Urothelial Cancer: POUT Trial Update

Enfortumab Vedotin-ejfv: Antibody-Drug Conjugate for Advanced Urothelial Carcinoma

Racial Disparities and Access to Care in Bladder Cancer

Risk-Adapted Approaches to Managing Muscle-Invasive Bladder Cancer

Based on FDA Review, Manufacturer Withdraws Atezolizumab for Use in Bladder Cancer

GU Symposium 2021: Neoadjuvant Gemcitabine, Cisplatin, and Pembrolizumab in Bladder Cancer

GU Symposium 2021: Neoadjuvant Durvalumab Plus Chemotherapy in Muscle-Invasive Urothelial Carcinoma

Are There Racial Disparities in BCG Treatment of Non–Muscle Invasive Bladder Cancer?

Durvalumab Indication Withdrawn in Advanced Bladder Cancer in the United States

GU Symposium 2021: Novel IL-15 Superagonist for Non–Muscle-Invasive Bladder Cancer

Does Biologic Sex Influence Progression of Bladder Cancer After BCG Treatment?

GU Symposium 2021: Enfortumab Vedotin Versus Chemotherapy for Advanced Urothelial Carcinoma

GU Symposium 2021: Impact of Gender on Surgical Outcomes After Radical Cystectomy

GU Symposium 2021: Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Cancer

Proliposomal Paclitaxel in Non–Muscle Invasive Bladder Cancer: Study Supports Move to Phase IIb

Durvalumab-Based Combination Therapy in Non–Muscle Invasive Bladder Cancer

Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma

FDA Brief: Novel Treatment of Upper Tract Urothelial Cancer Granted Fast Track Designation

Chronic Kidney Disease: Risk Factor for Muscle-Invasive Bladder Cancer?

Does Cystectomy Delay Affect Mortality in Bladder Cancer?

Neoadjuvant Chemotherapy Deferral in Patients Undergoing Cystectomy for Bladder Cancer

Are Individuals With Multiple Sclerosis at Higher Risk of Developing Bladder Cancer?

Kidney-Sparing Alternative Treatment of Low-Grade Upper Tract Urothelial Carcinoma

Are There Racial Disparities in Mortality in Muscle-Invasive Bladder Cancer?

Avelumab Plus Axitinib Under Study in Urothelial Cancer

Ureteral Obstruction Prior to Chemotherapy for Muscle-Invasive Bladder Cancer

Combination Immunotherapy for Urothelial Carcinoma: Phase Ib Interim Analysis

DDR Alterations and Outcomes With Immunotherapy for Advanced Urothelial Cancer